Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

Senan, S.; ÖZGÜROĞLU, MUSTAFA; Daniel, D.; Villegas, A.; Vicente, D.; Murakami, S.; Hui, R.; Faivre-Finn, C.; Paz-Ares, L.; Wu, Y.; Mann, H.; Dennis, P.; Antonia, S.

doi:10.1016/j.esmoop.2022.100410

Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

Senan S., ÖZGÜROĞLU M., Daniel D., Villegas A., Vicente D., Murakami S., ...Daha Fazla

ESMO OPEN, cilt.7, sa.2, 2022 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 7 Sayı: 2
Basım Tarihi: 2022
Doi Numarası: 10.1016/j.esmoop.2022.100410
Dergi Adı: ESMO OPEN
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
Anahtar Kelimeler: immunotherapy, radiation therapy, chemotherapy, surgery, multimodality therapy, RANDOMIZED CONTROLLED-TRIAL, PHASE-III, PREOPERATIVE CHEMOTHERAPY, INDUCTION CHEMOTHERAPY, SURGICAL RESECTION, RADIOTHERAPY, N2, SURGERY
İstanbul Üniversitesi Adresli: Hayır

Özet

Background: The phase III PACIFIC trial (NCT02125461) established consolidation durvalumab as standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC) and no disease progression following chemoradiotherapy (CRT). In some cases, patients with stage IIIA-N2 NSCLC are considered operable, but the relative benefit of surgery is unclear. We report a post hoc, exploratory analysis of clinical outcomes in the PACIFIC trial, in patients with or without stage IIIA-N2 NSCLC.